OrbusNeich Medical Group Holdings Limited

HKSE 6929.HK

OrbusNeich Medical Group Holdings Limited Revenue Per Share for the year ending December 31, 2023: USD 0.18

OrbusNeich Medical Group Holdings Limited Revenue Per Share is USD 0.18 for the year ending December 31, 2023, a -2.27% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.
  • OrbusNeich Medical Group Holdings Limited Revenue Per Share for the year ending December 31, 2022 was USD 0.19, a -6.39% change year over year.
  • OrbusNeich Medical Group Holdings Limited Revenue Per Share for the year ending December 31, 2021 was USD 0.20, a 31.64% change year over year.
  • OrbusNeich Medical Group Holdings Limited Revenue Per Share for the year ending December 31, 2020 was USD 0.15, a -7.71% change year over year.
  • OrbusNeich Medical Group Holdings Limited Revenue Per Share for the year ending December 31, 2019 was USD 0.17.
Key data
Date Revenue Per Share Dividend Per Share Free Cash Flow Per Share Return on Assets (ROA)
Market news
Loading...
SV Wall Street
HKSE: 6929.HK

OrbusNeich Medical Group Holdings Limited

Description

OrbusNeich Medical Group Holdings Limited, an investment holding company, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People's Republic of China, and the United States. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, coronary stents for implantation, non-compliant balloons for post-dilatation, and specialty catheters. Its product portfolio covers various treatment processes in percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. The company was founded in 2001 and is headquartered in Shatin, Hong Kong. OrbusNeich Medical Group Holdings Limited is a subsidiary of Harmony Tree Limited.

StockViz Staff

February 3, 2025

Any question? Send us an email